1、Digital HealthRadar 20242Summary1.Digital Health Radar Opening Insights3Startup Longlist52.InsightsOur Shortlist6Market Insights7A View to the Future113.Select Case StudiesCharco Neurotech12Avegen13TaraCares144.AppendixMethodology15Glossary and References163Digital Health Radar 2024Opening InsightsS

2、ince COVID,we and our clients have observed a discernible change in how healthcare is delivered to patients globally.Digital health is seen as a transformational part of this change in healthcare provision.This is evidenced by renewed impetus in the startup space with investment reaching$3 billion i

3、n 2021.Our first interviewee,Lucy Jung,founder and CEO of Charco Neurotech,noted this trend,highlighting the rise in healthcare-focused product development and technology.However,the situation is not entirely positive.In 2023 investment declined to$1.1 billion,indicating that other economic and geop

4、olitical developments may be leading to volatility.Factors such as the emergence of open-access GenAI,the war in Ukraine,the Palestine-Israel conflict,issues in the Gulf of Aden,rising gas prices,and general inflation may all play a part.Pharmas response to digital health has been mixed.Whilst Bioge

5、n closed its digital arm,Eli Lilly and Company released its own digital health solution:LillyDirect and AstraZeneca has taken the plunge to spin out its digital health development arm into Evinova,leading to mixed signals across the board.Utilising startups to supercharge innovation could be a way t

6、o bridge the gap for those cautionary Pharma companies wishing to expand.“When we started in 2019,there werent many people in the product development and tech area that were looking into healthcare.There was lots of research concepts but not many companies or support in this space.Im excited to see